![Alexander Denner](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Alexander Denner
Direktör/Styrelseledamot på
IRONWOOD PHARMACEUTICALS, INC.
Förmögenhet: 1 M $ per 2026-07-31
Profil
Alexander John Denner is the founder of Sarissa Capital Management LP, founded in 2012, where the title held is Chief Executive Officer & Chief Investment Officer.
Current jobs include Independent Director at Ironwood Pharmaceuticals, Inc. since 2020, Independent Director at Attralus, Inc. since 2021, and Member-Supervisory Board at Biogen GmbH since 2009.
Former jobs include Chairman & Chief Executive Officer at Sarissa Capital Acquisition Corp.
from 2020 to 2022, Non-Executive Chairman at Enzon Pharmaceuticals, Inc. from 2009 to 2013, Chairman at ARIAD Pharmaceuticals, Inc. from 2016 to 2017, Chairman at The Medicines Co. from 2018 to 2020, Independent Director at Amylin Pharmaceuticals, Inc. from 2009 to 2012, Director at Forest Laboratories, Inc., Director at ImClone LLC from 2006 to 2008, Independent Director at Biogen, Inc. from 2009 to 2023, Independent Director at VIVUS, Inc. from 2013 to 2015, Director at Mast Therapeutics, Inc. from 2006 to 2009, Director at Genzyme Corp., Executive Director at Morgan Stanley Investment Management, Inc. from 2001 to 2005, Senior Managing Director at Icahn Partners LP from 2006 to 2011, Managing Director at Icahn Partners Master Fund LP, Senior Managing Director at Icahn Capital LP from 2006 to 2011, Director at Biogen Idec New Ventures, Inc., Director at HyperMed, Inc., Director at Bioverativ, Inc. from 2017 to 2018, and Portfolio Manager at Viking Global Investors LP in 2005.
Education includes undergraduate degree from Massachusetts Institute of Technology and graduate and doctorate degrees from Yale University.
Kända innehav i offentliga företag
| Företag | Datum | Antal aktier | Värdering | Värderingsdatum |
|---|---|---|---|---|
| 2026-06-16 | 323 855 ( 0,2 % ) | 1 M $ | 2026-07-31 |
Aktiva positioner av Alexander Denner
| Företag | Position | Start |
|---|---|---|
| IRONWOOD PHARMACEUTICALS, INC. | Direktör/Styrelseledamot | 2020-11-09 |
Biogen GmbH
 Biogen GmbH Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and supplies pharmaceutical products | Direktör/Styrelseledamot | 2009-01-01 |
Sarissa Capital Management LP
 Sarissa Capital Management LP Investment ManagersFinance Sarissa seeks to achieve superior risk-adjusted returns by constructing a portfolio, primarily across healthcare and related sectors, where there is a significant discrepancy between market value and intrinsic value. They frequently use activism to close this discrepancy. The firm employs a fundamental, research-driven, value-oriented approach to identify potential investments. They conduct rigorous, fundamentals-based research. Sarissa is an activist firm and is included in SharkWatch50 as one of the 50 most prominent and impactful activist investors. | Verkställande Direktör | 2012-01-01 |
Attralus, Inc.
 Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Direktör/Styrelseledamot | 2021-09-08 |
Tidigare kända positioner av Alexander Denner
| Företag | Position | Slut |
|---|---|---|
| BIOGEN INC. | Direktör/Styrelseledamot | 2023-06-26 |
| SARISSA CAPITAL ACQUISITION CORP. | Verkställande Direktör | 2022-12-01 |
| THE MEDICINES COMPANY | Ordförande | 2020-04-01 |
| BIOVERATIV INC | Direktör/Styrelseledamot | 2018-03-08 |
| ARIAD PHARMACEUTICALS, INC. | Ordförande | 2017-02-16 |
Alexander Denners utbildningar
Erfarenheter
Innehade positioner
Aktiva
Inaktiva
Börsnoterade företag
Privata företag
Relationer
74
Första gradens relationer
25
Företag kopplade till första graden
Man
Kvinna
Styrelseledamöter
Chefer
Kopplade företag
| Privata företag | 25 |
|---|---|
Amylin Pharmaceuticals, Inc.
 Amylin Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes medicines for diabetes, obesity and cardiovascular diseases | Health Technology |
Enzon Pharmaceuticals, Inc.
 Enzon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops innovative therapeutics for cancer patients | Health Technology |
Forest Laboratories, Inc.
 Forest Laboratories, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and sells drug products | Health Technology |
ImClone LLC
 ImClone LLC BiotechnologyHealth Technology Develops novel therapeutic products and blood cell growth factors for the treatment of cancer | Health Technology |
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes small-molecule drugs for the treatment of cancer | Health Technology |
Biogen, Inc.
 Biogen, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and markets therapies for neurological and neurodegenerative diseases | Health Technology |
VIVUS, Inc.
 VIVUS, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops and commercializes next-generation therapies | Health Technology |
Viking Global Investors LP
 Viking Global Investors LP Investment ManagersFinance VGI is an active, long-term manager aiming to achieve maximum capital appreciation while mitigating general market risk by employing a hedged approach and taking short and long positions. The firm performs fundamental analysis to select investments primarily in public equity securities, but also in private equity and other financial instruments. They typically invest in companies located around the world that operate in a wide range of industries. | Finance |
The Medicines Co.
 The Medicines Co. Pharmaceuticals: MajorHealth Technology Operates as a biotechnology company that develops drugs for acute cardiovascular care | Health Technology |
Mast Therapeutics, Inc.
 Mast Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops novel therapies for serious or life-threatening diseases with significant unmet needs | Health Technology |
Genzyme Corp.
 Genzyme Corp. Pharmaceuticals: MajorHealth Technology Develops and manufactures therapies for rare diseases, multiple sclerosis, immunology & oncology | Health Technology |
Ironwood Pharmaceuticals, Inc.
 Ironwood Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets gastrointestinal products | Health Technology |
Morgan Stanley Investment Management, Inc.
 Morgan Stanley Investment Management, Inc. Investment ManagersFinance MSIM’s investment strategies span the risk/return spectrum across geographies, investment styles and asset classes, including equity, fixed income, alternatives and private markets. When considering their clients’ unique investment profiles, the firm applies a holistic approach, with a goal of incorporating the different factors affecting investors’ investment decisions. The firm combines top-down country allocation with bottom-up stock selection and disciplined risk management. | Finance |
Icahn Partners LP
 Icahn Partners LP Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Miscellaneous |
Icahn Partners Master Fund LP
 Icahn Partners Master Fund LP Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Miscellaneous |
Icahn Capital LP
 Icahn Capital LP Investment Trusts/Mutual FundsMiscellaneous Acts as Hedge Fund | Miscellaneous |
Sarissa Capital Management LP
Sarissa Capital Management LP Investment ManagersFinance Sarissa seeks to achieve superior risk-adjusted returns by constructing a portfolio, primarily across healthcare and related sectors, where there is a significant discrepancy between market value and intrinsic value. They frequently use activism to close this discrepancy. The firm employs a fundamental, research-driven, value-oriented approach to identify potential investments. They conduct rigorous, fundamentals-based research. Sarissa is an activist firm and is included in SharkWatch50 as one of the 50 most prominent and impactful activist investors. | Finance |
Massachusetts Institute of Technology
 Massachusetts Institute of Technology Finance/Rental/LeasingFinance Functions as a College/University | Finance |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Biogen Idec New Ventures, Inc.
 Biogen Idec New Ventures, Inc. Investment ManagersFinance Biogen Idec New Ventures' strategy is to select investments in companies developing innovative human therapeutic products or technologies that will drive product discovery and development more efficiently. Their specific areas of interest are companies in Biogen Idec's current therapeutic areas of neurology, oncology and immunology/inflammation, but they also seek opportunities outside these areas that fit their strategies for longer-term growth. The firm invests at all stages of development; most of their investments are in early-stage companies. They also look for investment opportunities where they can leverage their parent's resources and scientific and development expertise to support these investments. | Finance |
HyperMed, Inc.
 HyperMed, Inc. Medical DistributorsDistribution Services Develops medical imaging devices | Distribution Services |
Biogen GmbH
Biogen GmbH Pharmaceuticals: MajorHealth Technology Discovers, develops, manufactures and supplies pharmaceutical products | Health Technology |
Bioverativ, Inc.
 Bioverativ, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that engages in discovery, research, development and commercialization of therapies for hemophilia & blood disorders | Health Technology |
Attralus, Inc.
Attralus, Inc. Pharmaceuticals: MajorHealth Technology Develops novel pan-amyloid removal therapeutics | Health Technology |
Sarissa Capital Acquisition Corp.
 Sarissa Capital Acquisition Corp. Financial ConglomeratesFinance Operates as blank check company | Finance |
